#AntibodyTherapeutics
LightNews LightNews
antibodytx.bsky.social
Antibody Therapeutics (IF=4.8, Oxford University Press) ⚡ Research Highlight - A landscape of sequence variants in 51 commercial antibody therapeutics.
doi.org/10.1093/abt/...
#antibodydiscovery #antibodytherapeutics #biologics #sequencevariant #biosimilar #massspectrometry
September 25, 2026 at 1:51 PM
antibodytx.bsky.social
🎉 Exciting News for Antibody Therapeutics!
We are delighted to share that the 2025 Journal Impact Factor of Antibody Therapeutics has increased to 4.8, reaching a new all-time high from 4.5 last year!
#mab #antibody #antibodydiscovery #antibodytherapeutics #biologics #openaccess
June 21, 2026 at 3:28 AM
antibodytx.bsky.social
Antibody Therapeutics(IF=4.5, Oxford University Press)
🎉🎉🏆Papers of the Year Award 2025🏆🎉🎉
1. lnkd.in/eZJPPJ5X
2. lnkd.in/enDwP8hu
3. lnkd.in/eGiSt8V9
4. lnkd.in/eswXcn-P
We warmly congratulate all award-winning authors on their remarkable achievements.
#Antibody #Antibodies #AntibodyTherapeutics
January 19, 2026 at 9:40 PM
irat1onal.bsky.social
Accelerating Promising Biotech Innovation - Dr. Aliza Apple, Ph.D. - VP, Catalyze360 AI/ML and Global Head, Lilly TuneLab, Eli Lilly #DrugDiscoveryModels #AntibodyTherapeutics #InSilicoPropertyPredictions #ArtificialIntelligence #InnovationHubs www.youtube.com/watch?v=f8e6...
Dr. Aliza Apple, Ph.D. - VP, Catalyze360 AI/ML and Global Head, Lilly TuneLab, Eli Lilly
YouTube video by Progress, Potential, and Possibilities
www.youtube.com
October 9, 2025 at 5:18 PM
mscience.bsky.social
If you're attending the Sydney #AntibodyTherapeutics Conference this week be sure to shimmy your way to the Millennium Science - Unchained Labs booth to learn about the latest and greatest #antibody solutions!
May 7, 2025 at 1:29 AM
antibodytx.bsky.social
Antibody Therapeutics (IF=4.8, Oxford University Press) ⚡ Review Highlight -Reforming solid tumor treatment: the emerging potential of smaller format antibody-drug conjugate.
doi.org/10.1093/abt/...
#mab #mabs #antibody #antibodies #antibodydiscovery #antibodytherapeutics
August 18, 2026 at 3:33 PM
antibodytx.bsky.social
Antibody Therapeutics (IF=4.8, Oxford University Press) ⚡ Review Highlight -Bispecific and multispecific T-cell engagers: advancing the future of immunotherapy.
doi.org/10.1093/abt/...
#mab #mabs #antibody #antibodies #antibodydiscovery #antibodytherapeutics
August 21, 2026 at 4:23 PM
antibodytx.bsky.social
Antibody Therapeutics (IF=4.8, Oxford University Press) ⚡ Review Highlight -Current use and development of monoclonal antibodies for the treatment of systemic lupus erythematosus: a review.
doi.org/10.1093/abt/...
#mab #mabs #antibody #antibodydiscovery #antibodytherapeutics
September 2, 2026 at 7:07 PM
antibodytx.bsky.social
Antibody Therapeutics(IF=4.5, Oxford University Press)
📢📢Call for Proposals: GPCR-Targeting Antibodies 🧬
Covering discovery, engineering, structure, AI design & translational studies.
🗓 Proposal deadline: Feb 28, 2026
#AntibodyTherapeutics #GPCR #Biologics
January 27, 2026 at 2:16 PM
antibodytx.bsky.social
Antibody Therapeutics (IF=4.8, Oxford University Press) ⚡ Review Highlight -Practical advice in the development of a lyophilized protein drug product.
doi.org/10.1093/abt/...
#mab #mabs #antibody #antibodies #antibodydiscovery #antibodytherapeutics
August 19, 2026 at 7:34 PM
antibodytx.bsky.social
🎉 Great news! Antibody Therapeutics now has its own Wikipedia page!

Check out the journal's scope, history, and impact (IF: 4.8) here:
🔗 en.wikipedia.org/wiki/Antibod...
#AntibodyTherapeutics #Immunology #OpenAccess
Antibody Therapeutics - Wikipedia
en.wikipedia.org
August 17, 2026 at 1:44 PM
antibodytx.bsky.social
Antibody Therapeutics (IF=4.8, Oxford University Press) ⚡ Research Highlight -First site-specific conjugation method for native goat IgG antibodies via glycan remodeling at the conserved Fc region.
doi.org/10.1093/abt/...
#mabs #antibody #antibodydiscovery #antibodytherapeutics
September 8, 2026 at 1:52 PM
antibodytx.bsky.social
Antibody Therapeutics (IF=4.8, Oxford University Press) ⚡ Review Highlight -Structure and function of therapeutic antibodies approved by the US FDA in 2023.
doi.org/10.1093/abt/...
#mab #mabs #antibody #antibodies #antibodydiscovery #antibodytherapeutics
August 24, 2026 at 7:23 PM
keystonesymposia.bsky.social
Explore Antibodies as Drugs and Brain Drug Delivery! Present your research with a poster. Submit abstracts by January 27 (11:59pm MST).

keysym.us/KSAntibodyDr... or keysym.us/KSBrainDrugs25

#KSAntibodyDrugs25 #KSBrainDrugs25 #antibodytherapeutics #antibodydrugs #drugdelivery #brain #CNS
January 16, 2025 at 5:55 PM
antibodytx.bsky.social
Antibody Therapeutics (IF=4.8, Oxford University Press) ⚡ Research Highlight -A case study of a bispecific antibody manufacturability assessment and optimization during discovery stage and its implications.
doi.org/10.1093/abt/...
#mab #antibodies #antibodytherapeutics
August 31, 2026 at 1:59 PM
antibodytx.bsky.social
Antibody Therapeutics (IF=4.8, Oxford University Press) ⚡Announcement - We are delighted to welcome Dr. Christian Klein, from Ludwig Maximilian University of Munich, Germany, as a new Editorial Board Member of Antibody Therapeutics.
#antibodytherapeutics #editorialboard #biologics
August 5, 2026 at 4:47 PM
antibodytx.bsky.social
Antibody Therapeutics (IF=4.8, Oxford University Press) ⚡ Research Highlight -Novel ADC and γδ T cell engager targeting CDH17 for the therapy of gastrointestinal cancers.
doi.org/10.1093/abt/...
#mab #mabs #antibody #antibodies #antibodydiscovery #antibodytherapeutics
August 28, 2026 at 1:37 PM
decodescience.bsky.social
Sydney Antibody Therapeutics (SAT) 2025 Conference is now accepting registrations for its epic event on May 7th-8th. It's being held at...........The Taronga Zoo!!!!!

Decode Science are proud to be Platinum co-sponsors of this event with @twistbioscience.com

See you there :)

#antibodytherapeutics
March 31, 2025 at 9:17 PM
bcic.bsky.social
This week’s deal flow sends a clean signal: capital is not retreating from innovation—it is becoming more selective about where technical risk is taken and how it is transferred.
#BCIC #BiotechInvesting #AntibodyTherapeutics
#TCellEngagers #BispecificAntibodies #ADC
#GeneTherapy #RareDisease
In antibody therapeutics, large pharma continues to pay for platforms that explicitly address therapeutic index. The 百时美施贵宝-Janux Therapeutics collaboration around a tumor-activated T cell engager reinforces that conditional activation remains one of the most credible strategies for expanding the use of TCEs in solid tumors. When platform design is anchored in safety control rather than brute-force potency, preclinical assets can still command meaningful economics. A similar logic appears in autoimmune disease. 勃林格殷格翰’s billion-euro-scale bet on a TL1A×IL-23 bispecific reflects confidence that pathway convergence, rather than incremental single-target optimization, may be required to reset efficacy ceilings in chronic inflammatory diseases. Importantly, these deals continue to offload late-stage clinical and commercial execution to scaled operators, allowing early innovators to monetize platform risk earlier. What stands out this week, however, is the contrast provided by gene medicine. 礼来’s >$1.1B collaboration with Seamless Therapeutics around a programmable recombinease platform for hereditary hearing loss highlights that gene therapy capital is re-entering the market—but in a more disciplined form. The emphasis is no longer on editing novelty alone, but on programmability, precision, and clinical tractability. In many ways, this mirrors where antibody investing was a decade ago. Two cross-modality patterns are becoming clearer: - Platform optionality is favored over single-asset heroics - Safety, controllability, and manufacturability increasingly drive valuation - Big pharma prefers structured deals that preserve downside while securing long-term upside The antibody and gene therapy worlds are converging—not in modality, but in investment logic. The next winners will be platforms that convert uncertainty into engineering problems.
January 29, 2026 at 4:18 PM
bcic.bsky.social
Recent Biopharma Deal Activity Highlights Continued Cross-Border Collaboration and Platform Partnerships

Key reported developments
www.linkedin.com/posts/boston...
#bcic #biotech #biopharma #drugdevelopment #pharmadeals #antibodytherapeutics #adc #biotechinnovation #lifesciences #biotechinvestment #pharmastrategy | Boston Capital Investment Club
Recent Biopharma Deal Activity Highlights Continued Cross-Border Collaboration and Platform Partnerships Key reported developments • Innovent Biologics × Eli Lilly and Company Lilly – Strategic R&D c...
www.linkedin.com
March 6, 2026 at 7:32 AM
antibodytx.bsky.social
Antibody Therapeutics (IF=4.5, Oxford University Press) ⚡ Research Highlight - Challenges and solutions for upstream processing of complex biologics
academic.oup.com/abt/article/...

#mab #mabs #antibody #antibodies #antibodydiscovery #antibodytherapeutics #biologics #openaccess
Challenges and solutions for upstream processing of complex biologics
Statement of Significance Complex molecules present hurdles in expression, assembly, and posttranslational modification, thereby limiting titer and quality
academic.oup.com
April 21, 2026 at 1:59 AM
antibodytx.bsky.social
Antibody Therapeutics (IF=4.8, Oxford University Press) Research Highlight -IMM2510, a novel anti-PD-L1/VEGF bispecific antibody for cancer immunotherapy.
academic.oup.com/abt/article/...
#mab #mabs #antibody #antibodies #antibodydiscovery #antibodytherapeutics
IMM2510, a novel anti-PD-L1/VEGF bispecific antibody for cancer immunotherapy
Statement of Significance MM2510 is an Fc-engineered PD-L1 × VEGF bispecific antibody in which each anti-PD-L1 heavy chain is fused to VEGFR1 domain 2. Pre
academic.oup.com
June 27, 2026 at 11:50 AM
promegauk.bsky.social
Fc Effector Insight: Integrated workflow from lead generation to lot release.

Download the Fc Receptors guide covering Lumit® binding assays, ADCC/ADCP Reporter Assays & HiBiT® Target Cell Killing Bioassays at: https://ow.ly/boyr50Zgb4A

#AntibodyTherapeutics #FcReceptors
August 27, 2026 at 8:05 AM
newsramp.com
VERAXA Biotech (NASDAQ: VRXA) is advancing its BiTAC platform in antibody-drug conjugates and T-cell engagers, two areas drawing massive pharma investment. Its pipeline targets future partnerships, licensing deals, and asset transactions. #Biotech #AntibodyTherapeutics
Image from article
August 7, 2026 at 8:01 PM
d-and-d-world.bsky.social
KBI Biopharma is teaming up with Infinimmune to manufacture IFX-101, an experimental antibody for atopic dermatitis. The partnership combines AI-driven discovery with large-scale manufacturing expertise.

#News #Biotech #Pharma #AntibodyTherapeutics #DrugDevelopment #AtopicDermatitis #Healthcare
Infinimmune teams up with KBI Biopharma for antibody manufacturing
KBI Biopharma joins forces with Infinimmune to manufacture the latter’s monoclonal antibody for atopic dermatitis, IFX-101.
druganddeviceworld.com
September 9, 2025 at 7:03 PM